H Schuitemaker

H Schuitemaker's AcademicInfluence.com Rankings

H Schuitemaker

Physics

#5463

World Rank

#7300

Historical Rank

physics Degrees

Download Badge

Physics

H Schuitemaker's Degrees

PhD Physics University of Amsterdam
Masters Physics University of Amsterdam
Bachelors Physics University of Amsterdam

Why Is H Schuitemaker Influential?

(Suggest an Edit or Addition)

(See a Problem?)

H Schuitemaker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 (2021) (1283)
Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population (1992) (1146)
The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation (2010) (1129)
A new classification for HIV-1 (1998) (899)
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule (1992) (829)
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine (2021) (813)
Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics (1995) (737)
Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques (2020) (736)
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. (1994) (549)
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies (2012) (499)
Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys (2011) (481)
T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock (2000) (437)
Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture (1991) (339)
Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys (2013) (312)
Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection (1997) (309)
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes (2015) (301)
In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. (2000) (297)
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology (2015) (286)
Effects of CCR5- 32, CCR2-64I, and SDF-1 3A Alleles on HIV-1 Disease Progression: An International Meta-Analysis of Individual-Patient Data (2001) (282)
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys (2015) (275)
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (257)
Relation of phenotype evolution of HIV-1 to envelope V2 configuration. (1993) (252)
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. (1999) (233)
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans (2021) (232)
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. (2016) (232)
Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys (2016) (222)
A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism (2015) (216)
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) (2018) (214)
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. (2021) (211)
Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection (2008) (206)
The role of a stromal cell‐derived factor‐1 chemokine gene variant in the clinical course of HIV‐1 infection (1998) (205)
T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? (1993) (202)
The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? (1994) (193)
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (193)
Proliferation-dependent HIV-1 infection of monocytes occurs during differentiation into macrophages. (1992) (188)
Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. (2010) (184)
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study (1998) (173)
Prospects for a safe COVID-19 vaccine (2020) (173)
HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. (1999) (172)
Changing Virus‐Host Interactions in the Course of HIV‐1 Infection (1994) (168)
Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. (1996) (162)
CD39/Adenosine Pathway Is Involved in AIDS Progression (2011) (159)
Analysis of the Temporal Relationship between Human Immunodeficiency Virus Type 1 Quasispecies in Sequential Blood Samples and Various Organs Obtained at Autopsy (1998) (154)
Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera (1995) (153)
Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR (1995) (144)
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination (2021) (142)
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load (2015) (140)
OKT3 and IL-2 Treatment for Purging of the Latent HIV-1 Reservoir in Vivo Results in Selective Long-Lasting CD4+ T Cell Depletion (2001) (137)
The effect of plasma drug concentrations on HIV‐1 clearance rate during quadruple drug therapy (1998) (134)
Low-Level CD4+ T Cell Activation Is Associated with Low Susceptibility to HIV-1 Infection1 (2005) (134)
Association Study of Common Genetic Variants and HIV-1 Acquisition in 6,300 Infected Cases and 7,200 Controls (2013) (133)
Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. (2001) (133)
Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level (2010) (130)
The Development of CD4 Binding Site Antibodies during HIV-1 Infection (2012) (129)
International Network for Comparison of HIV Neutralization Assays: The NeutNet Report (2009) (124)
Alternative multidrug regimen provides improved suppression of HIV‐1 replication over triple therapy (1998) (122)
Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with nonprogressive infection. (1998) (120)
An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability (2016) (119)
Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain (1992) (114)
The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection (2008) (113)
International Network for Comparison of HIV Neutralization Assays: The NeutNet Report II (2009) (113)
Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. (1999) (111)
Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease (2007) (111)
Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression (2009) (111)
Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (109)
Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. (1993) (109)
Viral Replication Capacity as a Correlate of HLA B57/B5801-Associated Nonprogressive HIV-1 Infection1 (2007) (108)
Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1. (2000) (107)
Productive HIV‐1 infection of macrophages restricted to the cell fraction with proliferative capacity. (1994) (104)
Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression. (1999) (103)
GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. (2005) (103)
CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection. (1999) (103)
Clinical significance of HIV-1 coreceptor usage (2011) (103)
Evolution of Syncytium-Inducing and Non-Syncytium-Inducing Biological Virus Clones in Relation to Replication Kinetics during the Course of Human Immunodeficiency Virus Type 1 Infection (1998) (102)
Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection (2003) (102)
No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial (2012) (101)
Longer V1V2 Region with Increased Number of Potential N-Linked Glycosylation Sites in the HIV-1 Envelope Glycoprotein Protects against HIV-Specific Neutralizing Antibodies (2011) (101)
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection (2009) (100)
Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. (2010) (91)
Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. (2003) (89)
CCR5, GPR15, and CXCR6 Are Major Coreceptors of Human Immunodeficiency Virus Type 2 Variants Isolated from Individuals with and without Plasma Viremia (2005) (88)
In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. (1998) (88)
HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy (2008) (88)
Inactivated Viral Vaccines (2014) (86)
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (2022) (83)
Rapid Escape from Preserved Cross-Reactive Neutralizing Humoral Immunity without Loss of Viral Fitness in HIV-1-Infected Progressors and Long-Term Nonprogressors (2010) (83)
Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual (2003) (81)
Isolation and propagation of HIV-1 on peripheral blood mononuclear cells (2008) (79)
Phenotypic and Genotypic Comparisons of CCR5- and CXCR4-Tropic Human Immunodeficiency Virus Type 1 Biological Clones Isolated from Subtype C-Infected Individuals (2004) (78)
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (2020) (77)
cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. (1988) (77)
Faculty Opinions recommendation of The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. (2009) (76)
Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. (1998) (74)
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies (2015) (74)
Reversal of Human Immunodeficiency Virus Type 1 IIIB to a Neutralization-Resistant Phenotype in an Accidentally Infected Laboratory Worker with a Progressive Clinical Course (2001) (74)
Presence of the variant mannose‐binding lectin alleles associated with slower progression to AIDS (1998) (73)
Resistance of surface-dried virus to common disinfection procedures. (2007) (73)
Rapid CD4+ T-cell turnover in HIV-1 infection: a paradigm revisited. (1998) (71)
Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages (1994) (71)
Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. (1995) (70)
Increased Neutralization Sensitivity of Recently Emerged CXCR4-Using Human Immunodeficiency Virus Type 1 Strains Compared to Coexisting CCR5-Using Variants from the Same Patient (2006) (68)
Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity (2011) (67)
Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing (2011) (67)
Strong association between failure of T cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam Cohort Study (2000) (66)
Increased in vitro cytopathicity of CC chemokine receptor 5-restricted human immunodeficiency virus type 1 primary isolates correlates with a progressive clinical course of infection. (2003) (66)
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. (2013) (66)
Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G1 Phase of the Cell Cycle (2000) (66)
Toxicity and drug exposure in a quadruple drug regimen in HIV–1 infected patients participating in the ADAM study (2000) (65)
Broader tropism and higher cytopathicity for CD4+ T cells of a syncytium-inducing compared to a non-syncytium-inducing HIV-1 isolate as a mechanism for accelerated CD4+ T cell decline in vivo. (1996) (63)
Activity of Broadly Neutralizing Antibodies, Including PG9, PG16, and VRC01, against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Epidemic (2011) (63)
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses (2020) (62)
No evidence for an effect of the CCR5 delta32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1-infected injecting drug users. (1999) (62)
A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. (2018) (61)
Genome-wide association study implicates PARD3B-based AIDS restriction. (2011) (60)
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates (2018) (59)
Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics (2012) (59)
HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. (1994) (59)
Macrophage‐tropic HIV‐1 variants: initiators of infection and AIDS pathogenesis? (1994) (55)
The virucidal spectrum of a high concentration alcohol mixture. (2002) (54)
Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species (2012) (54)
Pathogenesis of Primary R5 Human Immunodeficiency Virus Type 1 Clones in SCID-hu Mice (2000) (54)
Phenotype of HIV-1 lacking a functional nuclear localization signal in matrix protein of gag and Vpr is comparable to wild-type HIV-1 in primary macrophages. (1999) (53)
Depletion of naive CD4 T cells by CXCR4-using HIV-1 variants occurs mainly through increased T-cell death and activation (2003) (52)
Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection. (2008) (51)
Susceptibility of in vitro stimulated PBMC to infection with NSI HIV-1 is associated with levels of CCR5 expression and beta-chemokine production. (2000) (51)
Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models. (2011) (50)
Cytopathicity of Human Immunodeficiency Virus Type 1 Primary Isolates Depends on Coreceptor Usage and Not Patient Disease Status (2001) (49)
Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. (2015) (49)
Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour (2004) (49)
In Vivo Evolution of X4 Human Immunodeficiency Virus Type 1 Variants in the Natural Course of Infection Coincides with Decreasing Sensitivity to CXCR4 Antagonists (2004) (48)
Chemokine receptors and the clinical course of HIV-1 infection. (1998) (48)
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment☆ (2020) (48)
Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data (2012) (47)
Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates (2007) (47)
Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. (1999) (46)
Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern (2021) (46)
HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity (2013) (45)
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP (2021) (44)
Viral safety of C1-inhibitor NF. (2007) (44)
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge (2018) (43)
Donor variation in in vitro HIV-1 susceptibility of monocyte-derived macrophages. (2009) (42)
Genome-Wide Association Scan in HIV-1-Infected Individuals Identifying Variants Influencing Disease Course (2011) (42)
PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine. (2013) (42)
In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. (2006) (41)
Highly active antiretroviral therapy with or without mycophenolate mofetil in treatment-naive HIV-1 patients (2004) (41)
Emergence of syncytium-inducing human immunodeficiency virus type 1 variants coincides with a transient increase in viral RNA level and is an independent predictor for progression to AIDS. (1998) (39)
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine with an Adenovirus 26 Vector Encoding Pre-Fusion F (Ad26.RSV.preF) in adults 60 years and older. (2020) (39)
The presence of the Trim5α escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase (2007) (38)
Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. (1996) (38)
Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples (1998) (38)
Viro‐immunological studies in acute HIV‐1 infection (1994) (38)
Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays (2009) (38)
Genome-Wide Association Study Identifies Single Nucleotide Polymorphism in DYRK1A Associated with Replication of HIV-1 in Monocyte-Derived Macrophages (2011) (38)
Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. (1997) (37)
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (37)
Increased Sensitivity to CD4 Binding Site-Directed Neutralization following In Vitro Propagation on Primary Lymphocytes of a Neutralization-Resistant Human Immunodeficiency Virus IIIB Strain Isolated from an Accidentally Infected Laboratory Worker (2004) (36)
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques (2021) (36)
Screening Low-Frequency SNPS From Genome-Wide Association Study Reveals a New Risk Allele for Progression to AIDS (2011) (36)
The effecT of TrIm 5 PolymorPhIsms on The clInIcal course of hIV-1 InfecTIon (2011) (36)
Susceptibility of Recently Transmitted Subtype B Human Immunodeficiency Virus Type 1 Variants to Broadly Neutralizing Antibodies (2007) (35)
Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees. (1998) (35)
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (34)
Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. (1992) (34)
Cross-reactive broadly neutralizing antibodies: timing is everything (2012) (34)
Cell turnover and cell tropism in HIV-1 infection. (2002) (34)
Cytopathic Effects of Non-Syncytium-Inducing and Syncytium-Inducing Human Immunodeficiency Virus Type 1 Variants on Different CD4+-T-Cell Subsets Are Determined Only by Coreceptor Expression (2001) (34)
Induction of monocyte proliferation and HIV expression by IL-3 does not interfere with anti-viral activity of zidovudine. (1990) (34)
Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus. (2005) (33)
HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. (2004) (33)
Early viral load and CD4+ T cell count, but not percentage of CCR5+ or CXCR4+ CD4+ T cells, are associated with R5-to-X4 HIV type 1 virus evolution. (2003) (33)
Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment (1995) (33)
A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. (2008) (32)
CTL escape and increased viremia irrespective of HIV-specific CD4+ T-helper responses in two HIV-infected individuals. (2006) (32)
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study (2021) (32)
Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process (1998) (32)
Molecular Evolution of Human Immunodeficiency Virus Type 1 upon Transmission between Human Leukocyte Antigen Disparate Donor-Recipient Pairs (2008) (32)
Evolution of R5 and X4 human immunodeficiency virus type 1 gag sequences in vivo: evidence for recombination. (2003) (31)
No difference in in vitro susceptibility to HIV type 1 between high-risk HIV-negative Ethiopian commercial sex workers and low-risk control subjects. (2001) (31)
Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. (2002) (31)
CC-chemokine receptor variants, SDF-1 polymorphism, and disease progression in 720 HIV-infected patients. SEROCO Cohort. Amsterdam Cohort Studies on AIDS. (1999) (31)
Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. (1995) (31)
Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. (2014) (31)
Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques (2021) (30)
CC Chemokine Receptor 5 Δ32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1–Infected Patients (2002) (30)
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector (2018) (29)
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate (2020) (29)
Inhibition of HIV-1 IIIB and clinical isolates by human parotid, submandibular, sublingual and palatine saliva. (2002) (29)
Effects of HIV‐1 Tat protein on human T cell proliferation (1992) (28)
Genetic composition of replication competent clonal HIV-1 variants isolated from peripheral blood mononuclear cells (PBMC), HIV-1 proviral DNA from PBMC and HIV-1 RNA in serum in the course of HIV-1 infection. (2010) (28)
Virulent HIV strains? (1993) (28)
Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic (2011) (28)
Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection. (2009) (28)
Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults. (2020) (27)
Association between an interleukin-4 promoter polymorphism and the acquisition of CXCR4 using HIV-1 variants (2003) (27)
Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern (2021) (27)
Temporal relationship between human immunodeficiency virus type 1 RNA levels in serum and cellular infectious load in peripheral blood. (1997) (27)
Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. (2010) (26)
Genome-Wide Association Study on the Development of Cross-Reactive Neutralizing Antibodies in HIV-1 Infected Individuals (2013) (26)
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (2016) (26)
Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition. (2012) (26)
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020) (25)
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques (2021) (25)
R5 Strains of Human Immunodeficiency Virus Type 1 from Rapid Progressors Lacking X4 Strains Do Not Possess X4-Type Pathogenicity in Human Thymus (1999) (24)
Early development of broadly reactive HIV-1 neutralizing activity in elite neutralizers (2014) (24)
Escape of human immunodeficiency virus type 1 from broadly neutralizing antibodies is not associated with a reduction of viral replicative capacity in vitro. (2007) (24)
Low Levels of Human Immunodeficiency Virus Type 1 DNA in High-Risk Seronegative Men (2005) (24)
Envelope V2 configuration and HIV-1 phenotype: clarification. (1995) (24)
Sensitivity of Primary R5 HIV-1 to Inhibition by Rantes Correlates with Sensitivity to Small-Molecule R5 Inhibitors (2005) (23)
R5 Human Immunodeficiency Virus Type 1 Infection of Fetal Thymic Organ Culture Induces Cytokine and CCR5 Expression (2005) (23)
Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. (1996) (23)
Causal Pathways of the Effects of Age and the CCR5-Δ32, CCR2-64I, and SDF-1 3′A Alleles on AIDS Development (2005) (22)
A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials (2019) (22)
Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine (2016) (22)
Absence of HIV-1 superinfection 1 year after infection between 1985 and 1997 coincides with a reduction in sexual risk behavior in the seroincident Amsterdam cohort of homosexual men. (2010) (22)
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (2021) (22)
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti–Zika Virus Vaccine (2021) (22)
Proliferation-dependent replication in primary macrophages of macrophage-tropic HIV type 1 variants. (1998) (22)
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection (2000) (21)
Prediction of Residual Time to AIDS and Death Based on Markers and Cofactors (2003) (21)
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice (2020) (21)
Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. (1996) (21)
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19 (2021) (20)
Kinetics of immune functions and virus replication during HIV-1 infection. (1997) (20)
Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution. (2003) (20)
Impact of host cell variation on the neutralization of HIV-1 in vitro (2009) (19)
Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. (1998) (19)
High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity. (2010) (19)
Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS. (2011) (19)
Early replication steps but not cell type-specific signalling of the viral long terminal repeat determine HIV-1 monocytotropism. (1993) (19)
Comparison of in vivo and in vitro evolution of CCR5 to CXCR4 coreceptor use of primary human immunodeficiency virus type 1 variants. (2011) (19)
HIV-1 Replication Fitness of HLA-B*57/58:01 CTL Escape Variants Is Restored by the Accumulation of Compensatory Mutations in Gag (2013) (19)
Immunization with Recombinant HLA Classes I and II, HIV-1 gp140, and SIV p27 Elicits Protection against Heterologous SHIV Infection in Rhesus Macaques (2011) (18)
Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection (2021) (18)
Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission (2011) (17)
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques (2021) (17)
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. (2018) (17)
Analysis of CD8+ T lymphocyte-mediated nonlytic suppression of autologous and heterologous primary human immunodeficiency virus type 1 isolates. (1997) (17)
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant (2021) (17)
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22). (2020) (16)
Both R5 and X4 Human Immunodeficiency Virus Type 1 Variants Persist during Prolonged Therapy with Five Antiretroviral Drugs (2002) (16)
Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations (2019) (16)
Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. (1995) (16)
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge (2018) (16)
Development of a replication‐deficient adenoviral vector‐based vaccine candidate for the interception of HPV16‐ and HPV18‐induced infections and disease (2017) (16)
Efficient inhibition of both syncytium‐inducing and non‐syncytium‐inducing wild‐type HIV‐1 by lamivudine in vivo (1998) (15)
IL4 and IL10 as potent inhibitors of HIV1 replication in macrophages in vitro: a role for cytokines in the in vivo virus host range? (1994) (15)
The Role of Innate APOBEC3G and Adaptive AID Immune Responses in HLA-HIV/SIV Immunized SHIV Infected Macaques (2012) (15)
Single Nucleotide Polymorphism in Gene Encoding Transcription Factor Prep1 Is Associated with HIV-1-Associated Dementia (2012) (15)
HIV tropism and CD4+ T-cell depletion (2002) (15)
Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. (2012) (15)
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control (2011) (15)
Evolution of Human Immunodeficiency Virus Type 1 in a Patient with Cross-Reactive Neutralizing Activity in Serum (2011) (14)
Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. (2015) (14)
Evidence for a post-entry barrier to R5 HIV-1 infection of CD4 memory T cells (2001) (14)
Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model (2013) (14)
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform (2017) (14)
Conversion rate towards a syncytium inducing (SI) phenotype during different stages of HIV infection and prognostic value of SI phenotype for survival after aids diagnoses (1997) (13)
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. (2001) (13)
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial (2022) (13)
Evaluation of pre-screening methods for the identification of HIV-1 superinfection. (2010) (13)
Increased Neutralization Sensitivity and Reduced Replicative Capacity of Human Immunodeficiency Virus Type 1 after Short-Term In Vivo or In Vitro Passage through Chimpanzees (2000) (13)
Persistence of Viral HLA-DR- CD4 T-Cell Reservoir during Prolonged Treatment of HIV-1 Infection with a Five-Drug Regimen (2002) (13)
No Selection for CCR5 Coreceptor Usage during Parenteral Transmission of Macrophagetropic Syncytium-Inducing Human Immunodeficiency Virus Type 1 (2001) (13)
Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial (2022) (13)
The evolution of human immunodeficiency virus type-1 (HIV-1) envelope molecular properties and coreceptor use at all stages of infection in an HIV-1 donor-recipient pair. (2012) (13)
Biological and Molecular Aspects of HIV-1 Coreceptor Usage (2003) (13)
The History of HIV-1 Biological Phenotypes Past , Present and Future (1998) (12)
Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers (2020) (12)
Correction: Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination (2016) (12)
Emergence of monoclonal antibody b12-resistant human immunodeficiency virus type 1 variants during natural infection in the absence of humoral or cellular immune pressure. (2010) (12)
Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study. (2014) (11)
T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates. (2007) (11)
Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. (1997) (11)
Host Genetic Factors in the Clinical Course of HIV-1 Infection: Chemokines and Chemokine Receptors (2002) (11)
Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys (2018) (11)
A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations (2017) (11)
CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients. (2002) (11)
Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. (2011) (11)
The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype. (2016) (10)
Low level of HIV-1 evolution after transmission from mother to child (2014) (10)
Determination of co-receptor usage of HIV-1. (2005) (10)
Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations (2019) (10)
Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs (2015) (10)
Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. (2007) (10)
Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. (2005) (10)
Viral and cellular determinants of HIV‐1 replication in macrophages (1996) (10)
Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2021) (9)
A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2–specific immune responses in rhesus macaques (2022) (9)
Dynamics of the Pool of Infected Resting Cd4 Hla-Dr- T Lymphocytes in Patients Who Started a Triple Class Five-Drug Antiretroviral Regimen During Primary HIV-1 Infection (2002) (9)
Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients. (2005) (9)
HIV tropism (1993) (9)
Immunogenicity of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques (2020) (8)
CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus (2017) (8)
HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression (2012) (8)
HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans (2013) (7)
Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models. (2021) (7)
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells. (2007) (7)
Brunenders: a partially attenuated historic poliovirus type I vaccine strain. (2015) (7)
Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials (2022) (7)
Molecular determinants of human immunodeficiency virus type I phenotype variability (1996) (7)
Determination of cell tropism of HIV-1. (2005) (7)
An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model (2018) (7)
HIV-1 transmission and viral adaptation to the host (2012) (6)
The Presence of CXCR4-Using HIV-1 Prior to Start of Antiretroviral Therapy Is an Independent Predictor of Delayed Viral Suppression (2013) (6)
SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques (2021) (6)
Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library. (2002) (6)
The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization (2021) (6)
CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variants. (2008) (5)
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector–based COVID‐19 vaccine (2022) (5)
A sweet surprise for HIV broadly neutralizing antibodies (2012) (5)
902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults (2019) (5)
Correlations between HIV-1 clades and HIV-1 antibody neutralization sensitivity: significant for vaccine development? (2010) (5)
OA06-05. Adaptation of HIV-1 to the human immune system at the population level is driven by protective HLA-B alleles (2009) (5)
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (2022) (5)
Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine. (2015) (4)
Lower Broadly Neutralizing Antibody Responses in Female Versus Male HIV-1 Infected Injecting Drug Users (2019) (4)
Differential Characteristics of Cytotoxic T Lymphocytes Restricted by the Protective HLA Alleles B*27 and B*57 in HIV-1 Infection (2014) (4)
Efficacy and Safety of a Booster Regimen of Ad26.COV2.S Vaccine against Covid-19 (2022) (4)
Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice (2020) (4)
Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6® cell-line: a phase 1 randomized controlled trial in adults (2020) (4)
P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group (2009) (4)
Reply to George and to Stapleton et al. Reply on: GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study J Infect Dis. 2005 Mar 1;191(5):678-85 (2005) (4)
Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing (2021) (4)
Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels (2022) (4)
Gag sequence variation in a human immunodeficiency virus type 1 transmission cluster influences viral replication fitness. (2013) (3)
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates (2018) (3)
Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies (2016) (3)
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (3)
HIV-1 isolation from infected peripheral blood mononuclear cells. (2014) (3)
Abstracts of papers and posters (2005) (3)
P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level (2009) (3)
Correlation between HIV‐1 seropositivity and prevalence of a γ‐secretase polymorphism in two distinct ethnic populations (2009) (3)
Reduced Prevalence of the CCR 5 D 32 Heterozygous Genotype in Human Immunodeficiency Virus – Infected Individuals with AIDS Dementia Complex (1999) (3)
A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. (2018) (3)
HIV-1 Subtype C Gag-Specific T-Cell Responses in Relation to Human Leukocyte Antigens in a Diverse Population of HIV-Infected Ethiopians (2007) (3)
Impact of CCR5 Δ32/+ Deletion on Herpes Zoster Among HIV-1-Infected Homosexual Men (2006) (2)
Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate (2020) (2)
Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters (2022) (2)
Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine (2022) (2)
HIV-1 Infection HLA B 57 / B 5801-Associated Nonprogressive Viral Replication Capacity as a Correlate of Kootstra and Hanneke (2007) (2)
Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection (vol 23, pg 19, 2009) (2010) (2)
Cross-reactive neutralizing activity in HIV-1 infected injecting drug users (2012) (2)
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age (2022) (2)
Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants. (2000) (2)
Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques (2022) (2)
CC chemokine receptor 5 delta 32 and CC chemokine receptor 2 64 I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (2)
Biological Properties of HIV-1 and Their Relevance for Aids Pathogenesis (1999) (2)
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (2)
HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals (2012) (2)
No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients (2007) (2)
AIDS Pathogenesis (2000) (2)
Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization (2012) (1)
against recently transmitted subtype B HIV-1 variants from early and late in the 2 (2011) (1)
UvA-DARE ( Digital Academic Repository ) CD 39 / Adenosine Pathway Is Involved in AIDS Progression (2011) (1)
Viral and Cellular Requirements for HIV-1 Infection in Monocytes1 (1992) (1)
Chapter 2 Inactivated Viral Vaccines (2017) (1)
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (1)
Negatively charged albumins (1999) (1)
Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models (2022) (1)
Further studies into the mechanism of interaction of negatively charged human serum albumins with the V3 loop of the HIV-1 envelope protein Gp120 (1995) (1)
HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity (2013) (1)
UvA-DARE (Digital Academic Repository) Clinical significance of HIV-1 coreceptor usage (1)
WITHDRAWN: Loss of control of viremia in HIV-1 seroconverters with best prognosis and lowest viral load at setpoint (2002) (1)
Peptide inhibition experiments. (2013) (1)
IL-10 and HIV-1 Replication (1995) (1)
cif-Diamminedichloroplatinum ( II )-resistant Sublines Derived from Two Human Ovarian Tumor Cell Lines 1 (2006) (1)
Cytotoxic T lymphocyte responses in HIV-1-infected long-term nonprogressors: lessons for vaccine design (2008) (1)
Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics (2012) (1)
Standardization of HIV Neutralization Assays for Use in Vaccine Research and Clinical Trials: Results from the NeutNet Working Group (2008) (1)
Proceedings 23rd International Symposium on Controlled Release of Bioactive Materials (1996) (1)
P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression (2009) (1)
RECENT DEVELOPMENT ON RESEARCH IN AIDS PATHOGENESIS (1994) (1)
mulTI-cohorT GeneTIc assocIaTIon sTudy reVeals cXcr 6 as a new chemokIne recePTor InVolVed In aIds lonG-Term non-ProGressIon (2011) (1)
Faculty Opinions recommendation of Genome-scale RNAi screen for host factors required for HIV replication. (2008) (0)
Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization (2012) (0)
P09-14. Emergence of b12 resistant rapidly replication HIV-1 variants during natural infection in the absence of humoral or cellular immune pressure (2009) (0)
LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials (2021) (0)
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease (2021) (0)
Replication competent HIV-1 quasispecies obtained via clonal virus isolation from peripheral blood mononuclear cells is genetically highly similar to the contemporaneous HIV-1 quasispecies in plasma (2009) (0)
Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer (2022) (0)
Sequence Variation intheThirdVariable DomainoftheHumanImmunodeficiency Virus Type1gpl20Molecule (1992) (0)
Interference ofInterleukin-10 withHuman Immunodeficiency VirusType1Replication inPrimary Monocyte- Derived Macrophages (1994) (0)
Biological Phenotype ofHumanImmunodeficiency VirusType1 Clones atDifferent Stages ofInfection: Progression ofDisease IsAssociated with a Shift fromMonocytotropic to T-Cell-Tropic VirusPopulations (1992) (0)
Negatively charged human serum albumins as inhibitors of HIV-1 replication: mechanism of action, in vitro activity against distinct HIV-1 isolates and in vivo efficacy in mice (1997) (0)
Polymorphism in HIV-1 dependency factor PDE8A affects gene expression and HIV-1 replication in primary macrophages (2011) (0)
CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer (2022) (0)
CCR5 Δ32 heterozygosity is an early independent progression marker for AIDS in human immunodeficiency virus type 1 infected subjects (1997) (0)
P07-04. HIV-1 evolution in mother to child transmission and pediatric disease progression (2009) (0)
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques (2020) (0)
HIV-1 envelope characteristics that coincide with the development of cross-reactive neutralizing activity in HIV-1 infected patients (2011) (0)
Kinetics of HIV-1 specific cytotoxic T lymphocyte responses and viral load in the natural history of HIV-1 infection☆ (1997) (0)
CONCISE COMMUNICATIONS Reduced Prevalence of the CCR5 D32 Heterozygous Genotype in Human Immunodeficiency Virus-Infected Individuals with AIDS Dementia Complex (1999) (0)
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge (2018) (0)
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters (2020) (0)
Negatively charged human serum albumins as inhibitors of HIV-1 replication: Mechanism of action and in vivo efficacy in mice (1996) (0)
Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets (2022) (0)
UvA-DARE (Digital Academic Repository) Virus and host determinants of HIV-1 infection and AIDS pathogenesis (2012) (0)
CHAPTER 5 – Viral and Host Determinants of HIV-1 Disease Progression (2008) (0)
2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years (2019) (0)
Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response. (2017) (0)
Negatively charged human serum albumins: Inhibition of replication of primary HIV-1 isolates and biomolecular interaction with gp120 (1994) (0)
Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice (2022) (0)
HIV-1 escapes from N332-directed antibody neutralization in an elite neutralizer by envelope glycoprotein elongation and introduction of unusual disulfide bonds (2016) (0)
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption (2020) (0)
HIV-1 intra-host evolutionary processes: efficient hypothesis testing through (2010) (0)
Faculty Opinions recommendation of Characteristics of the earliest cross-neutralizing antibody response to HIV-1. (2011) (0)
UvA-DARE (Digital Academic Repository) CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients (2002) (0)
Faculty Opinions recommendation of Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. (2009) (0)
RCT Abstract - Ad26.COV2.S immunogenicity in a Phase 2 trial at different booster dose levels and schedule intervals in adults (2021) (0)
Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study. (2022) (0)
Faculty Opinions recommendation of Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. (2007) (0)
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola (2022) (0)
HIV-1 sensitivity to neutralization : biological and molecular studies (2009) (0)
Cross-reactive neutralizing activity in HIV-1 infected injecting drug users (2012) (0)
Faculty Opinions recommendation of CD8+ T cells from SIV elite controller macaques recognize Mamu-B*08-bound epitopes and select for widespread viral variation. (2007) (0)
Faculty Opinions recommendation of HIV-1 adaptation to NK-cell-mediated immune pressure. (2011) (0)
Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models (2023) (0)
Broadly reactive neutralizing activity in HIV-1 infected injecting drug users (2016) (0)
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. (1998) (0)
Comment on Mosier and Sieburg. (1995) (0)
not interfere with anti-viral activity of zidovudine Induction of monocyte proliferation and HIV expression by IL-3 does (2011) (0)
Diminished Human Immunodeﬁciency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G 1 Phase of the Cell Cycle (2000) (0)
CoV-2 infection in Syrian hamsters and does not enhance respiratory disease (2021) (0)
Chapter 9 An HIV elite neutralizer as a blueprint for the induction of neutralizing antibodies (2016) (0)
HIV-1 envelope glycoprotein characteristics that correlate with the development of cross-reactive neutralizing activity in HIV-1 infected individuals (2012) (0)
Evolution of Human Immunodeﬁciency Virus Type 1 in a Patient with Cross-Reactive Neutralizing Activity in Serum (cid:1) (2011) (0)
Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques (2022) (0)
The role of polymorphisms in chemokines and chemokine receptors in the clinical course of HIV-1 infection (2004) (0)
Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques (2023) (0)
from Two Human Ovarian Tumor Cell Lines-Diamminedichloroplatinum ( II )-resistant Sublines Derived cis Updated (2006) (0)
Hanneke Phase of the Cell Cycle 1 in Early G Transport in Primary Macrophages Arrested Type 1 Reverse Transcription and Nuclear Diminished Human Immunodeficiency Virus (2000) (0)
Deviation from standard dose-response curve by bnMAbs in a U87 target cell assay. (2015) (0)
Faculty Opinions recommendation of Immune-driven recombination and loss of control after HIV superinfection. (2008) (0)
envGeneVariation amongEight Related HumanImmunodeficiency VirusType1Clones: Evidence forInVivoRecombination andDeterminants of Cytotropism outside theV3Domain (1992) (0)
PP 8.6 – 00089 Ad26/MVA Mosaic vaccine induced antibody responses with limited cross-reactivity to CRF01_AE infections (2022) (0)
CCR5 Genotype and the Clinical Course of HIV-1 Infection (1998) (0)
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters (2022) (0)
P19-08. Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques (2009) (0)
Use of Immunological and Viral Parameters to Predict Progression of HIV Infection During Natural Course and Antiretroviral Treatment (1997) (0)
P19-20. Allogeneic stimulation of the anti-viral APOBEC3G in human CD4+ T cells and prevention of SHIV infectivity in macaques immunized with HLA antigens (2009) (0)
Abstracts of papers clinical pharmacological meeting (2005) (0)
Dissecting the humoral antibody specificity in relation to virus evolution in pediatric HIV infection (2008) (0)
UvA-DARE ( Digital Academic Repository ) Detection of inferred CCR 5-and CXCR 4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing (2011) (0)
Evolution of CCR5 using human immunodeficiency virus type 1 in relation to CCR5∆32 host genetic background (2009) (0)
Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2 (2023) (0)
Faculty Opinions recommendation of R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch. (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With H Schuitemaker?

H Schuitemaker is affiliated with the following schools:

Leiden University
Ghent University
University of Amsterdam
Utrecht University